NCT06600659 A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
| NCT ID | NCT06600659 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Hematopoietic and Lymphatic System Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-11-02 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2023-11-02 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.
Eligibility Criteria
Inclusion Criteria: * Followed by pediatric hematology/oncology * Receiving recombinant Erwinia asparaginase for treatment of malignancy Exclusion Criteria: * Patients \< 1 year of age * Patients who have previously received recombinant Erwinia asparaginase within the past two weeks
Contact & Investigator
Catherine E. Martin, PharmD, RPh
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06600659 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Hematopoietic and Lymphatic System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06600659 currently recruiting?
Yes, NCT06600659 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06600659 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06600659 clinical trial?
NCT06600659 is sponsored by Mayo Clinic. The principal investigator is Catherine E. Martin, PharmD, RPh at Mayo Clinic in Rochester. The trial plans to enroll 10 participants.